Medipharm Labs Corp Cash Flow-to-Debt Ratio
Medipharm Labs Corp cash flow-to-debt ratio. Medipharm Labs Corp (LABS) has a Cash Flow-to-Debt Ratio of -0.09x as of March 2026, meaning its operating cash flow of CA$-778.00K could theoretically repay 0% of its total liabilities (CA$8.52 Million) in one year. Check earnings quality score of Medipharm Labs Corp to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Medipharm Labs Corp (2016–2025)
Cash flow-to-debt ratio of Medipharm Labs Corp from 2016 to 2025. Historical debt coverage capacity for Medipharm Labs Corp across 10 annual periods. Check Medipharm Labs Corp investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Medipharm Labs Corp Cash Flow-to-Debt Ratio by Year (2016–2025)
Medipharm Labs Corp cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Medipharm Labs Corp. For the full cash flow conversion analysis, see LABS cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.55x | CA$-5.50 Million | CA$9.93 Million | ▼ -20.3% |
| 2024 | -0.46x | CA$-4.86 Million | CA$10.55 Million | ▲ +59.2% |
| 2023 | -1.13x | CA$-12.34 Million | CA$10.93 Million | ▲ +33.3% |
| 2022 | -1.69x | CA$-16.07 Million | CA$9.49 Million | ▼ -18.1% |
| 2021 | -1.43x | CA$-13.21 Million | CA$9.21 Million | ▼ -51.1% |
| 2020 | -0.95x | CA$-37.77 Million | CA$39.82 Million | ▼ -41.2% |
| 2019 | -0.67x | CA$-25.27 Million | CA$37.60 Million | ▲ +10.0% |
| 2018 | -0.75x | CA$-11.11 Million | CA$14.89 Million | ▼ -1235.1% |
| 2017 | 0.07x | CA$166.00K | CA$2.52 Million | ▲ +105.6% |
| 2016 | -1.17x | CA$-54.69K | CA$46.73K | — |